Which pre-treatment evaluation is important before initiating anti-TNF therapy?

Which pre-treatment evaluation is important before initiating anti-TNF therapy?

• A. TB screening only
• B. Hepatitis C status assessment only
• C. Screening for latent TB with tuberculin skin test or IGRA, chest imaging; hepatitis B status; baseline vaccines
• D. Genetic testing for TPMT

Answer: (C)

The key idea is reducing infectious risks before starting anti-TNF therapy. Anti-TNF agents weaken a crucial part of the immune system that protects against infections like tuberculosis, and they can also trigger reactivation of hepatitis B in people who have been exposed. So, the pre-treatment workup should screen for latent TB (using a tuberculin skin test or IGRA) and include chest imaging to rule out active TB. At the same time, it’s important to assess hepatitis B status (HBsAg, anti-HBs, anti-HBc) because HBV reactivation can occur with TNF inhibitors and may require antiviral management. Finally, ensuring baseline vaccines are up to date helps prevent illnesses that could be severe when immune suppression is underway. This approach—TB screening with tests and imaging, HBV status assessment, and updating vaccines—covers the main infection risks associated with anti-TNF therapy and is why it’s the best choice. TPMT genetic testing is not relevant for anti-TNF agents, as that test guides thiopurine use, not anti-TNF therapy.

The key idea is reducing infectious risks before starting anti-TNF therapy. Anti-TNF agents weaken a crucial part of the immune system that protects against infections like tuberculosis, and they can also trigger reactivation of hepatitis B in people who have been exposed. So, the pre-treatment workup should screen for latent TB (using a tuberculin skin test or IGRA) and include chest imaging to rule out active TB. At the same time, it’s important to assess hepatitis B status (HBsAg, anti-HBs, anti-HBc) because HBV reactivation can occur with TNF inhibitors and may require antiviral management. Finally, ensuring baseline vaccines are up to date helps prevent illnesses that could be severe when immune suppression is underway. This approach—TB screening with tests and imaging, HBV status assessment, and updating vaccines—covers the main infection risks associated with anti-TNF therapy and is why it’s the best choice. TPMT genetic testing is not relevant for anti-TNF agents, as that test guides thiopurine use, not anti-TNF therapy.